Establishing AMP-activated protein kinase as a regulator of adipose stem cell plasticity and function in health and disease
Establishing AMP-activated protein kinase as a regulator of adipose stem cell plasticity and function in health and disease
批准号:
BB/W009633/1
负责人:
Alice Pollard
金额:
$51.48万
依托单位:
依托单位国家:
英国
项目类别:
Fellowship
财政年份:
2022
资助国家:
英国
项目状态:
未结题
起止时间:
2022 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
To grow, replicate and function, cells must sense and respond to their environment. Energy, in the form of adenosine triphosphate (ATP) is required for all cellular processes; to build proteins, replicate DNA, repair membranes and fight infections. To maintain optimal ATP concentrations, multi-protein systems continuously monitor nucleotide levels within the cell, driving growth and proliferation when ATP is plentiful, and by halting energy expenditure and initiating catabolism when ATP is scarce. One such network is governed by AMP-activated protein kinase (AMPK), an enzyme found in almost all organisms, responsible for directly sensing cellular energy levels. Activation of AMPK under energy stress drives the breakdown of energy stores and the removal of damaged or malfunctioning mitochondria (mitophagy), where the majority of ATP is generated. AMPK activation also increases the production of new, healthy mitochondria (biogenesis), leading to efficient ATP production, and encourages the uptake of glucose by the cell, to restore and maintain ATP. AMPK therefore presents an attractive drug target for the treatment of many diseases in which alterations in energy homeostasis feature prominently. Stem cells reside in most tissues, and are responsible for tissue maintenance and repair after damage. Metabolic diseases, such as obesity, diabetes and cardiovascular disease, often occur when energy balance is dysregulated, and are difficult to reverse with lifestyle change alone. Under conditions of metabolic stress, such as inflammation, hypoxia and cell exhaustion, these stem cells do not respond appropriately and the damage becomes irreversible. This process is also true of aging, when stem cells that reach their limits of self-renewal are no longer capable of tissue repair.White adipose tissue, a specialised organ primarily responsible for hormone production and the safe storage of lipids, is often implicated in metabolic disease. Excessive expansion of white adipose tissue leads to adipocyte death, systemic inflammation and insulin resistance, hallmarks of metabolic syndrome. Adipose-derived stem cells (ADSCs) share many features of pluripotent stem cells, capable of forming a diverse range of cell types, including cartilage, bone, skeletal and cardiac muscle. The combination of accessibility and plasticity make ADSCs attractive for targeted stem cell therapies in regenerative and restorative medicine. Our previous work identified a novel population of adipocytes, which we termed SMART cells, generated by genetically activating AMPK in a mouse model of obesity. These cells have a high mitochondrial content, increased mitophagy and express proteins usually found in muscle that allow them to generate heat, protecting the mice from diet-induced obesity and associated organ damage. As SMART cells express these muscle-specific proteins when stimulated in culture, they may be useful for the treatment of metabolic and age-related disease. However, little is known about the origin of these cells, or why they develop instead of normal white adipocytes when AMPK is active. Our aim is to understand the role of AMPK in the development of normal human adipose tissue, and the consequence of metabolic alterations at key points in stem cell differentiation on cell fate and function. Using human immortalised adipocyte derived stem cells (h-iADSCs), and fresh human ADSCs, we aim to establish the role of AMPK in adipose stem cell maintenance, in the specification of cell lineage, and in the resulting function of the mature adipocyte. The work will also explore the effect of metabolic instability on adipocyte lineage and function by isolating ADSCs from patients with metabolic disease. To determine the therapeutic value of AMPK activation, we will transplant patient-derived ADSCs, treated with AMPK activator C455, into mice, where we will assess their ability to form whole adipose tissue, and their effect on whole-body energy homeostasis.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
AMPK activation protects against prostate cancer by inducing a catabolic cellular state.
AMPK激活通过诱导分解代谢的细胞状态来预防前列腺癌。
DOI:
10.1016/j.celrep.2023.112396
发表时间:
2023-04-25
期刊:
Cell reports
影响因子:
8.8
作者:
[]
通讯作者:
国内基金
海外基金
登录
查看更多内容
可注射型CS@AMP复合水凝胶的构建及其调控牙周微环境促进组织再生的机制研究
-
批准号:2026JJ30036
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:覃佐东
-
依托单位:
转录因子DasR的酰基化修饰与c-di-AMP互作调控红霉素合成的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:尤迪
-
依托单位:
基于茶黄素的金属多酚纳米递送系统靶向抑制细菌c-di-AMP在牙周炎中的作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:万书成
-
依托单位:
AMP通过AMPK/FoxO1调控AS肉鸡肺血管重构发生的作用机制
-
批准号:
-
项目类别:省市级项目
-
资助金额:15.0万元
-
批准年份:2024
-
负责人:李英
-
依托单位:
利用多功能AMP-连接酶的底物宽泛性改造脂肽类抗生素SF2768的生物合成途径
-
批准号:32370087
-
项目类别:面上项目
-
资助金额:50万元
-
批准年份:2023
-
负责人:何璟
-
依托单位:
绵羊肺炎支原体c-di-AMP降解酶PdeM的结构与功能研究
-
批准号:32360877
-
项目类别:地区科学基金项目
-
资助金额:32万元
-
批准年份:2023
-
负责人:郝秀静
-
依托单位:
Monge-Ampère方程和k-Hessian方程解的存在性与边界渐近行为研究
-
批准号:12371112
-
项目类别:面上项目
-
资助金额:44.00万元
-
批准年份:2023
-
负责人:张学梅
-
依托单位:
抛物型Monge-Ampère方程的新探索
-
批准号:12371200
-
项目类别:面上项目
-
资助金额:43.5万元
-
批准年份:2023
-
负责人:保继光
-
依托单位:
一般凸区域上退化Monge-Ampère方程解的整体正则性
-
批准号:12301250
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:吴雅婷
-
依托单位:
Monge-Ampère方程的外Liouville定理及相关问题
-
批准号:12301249
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:贾小标
-
依托单位: